. 2022 Jul 7;32(9):3023–3033. doi: 10.1007/s11695-022-06189-4

Table 5.

Comparison of the early and late impacts of PRYGB and RRYGB on main associated medical conditions

	n = total		No change		Improved				${Score}^{a}$	Adj. prop ${OR}^{b}$ (95% CI)	P
	n = total		n	%	n	%	n	%	${Score}^{a}$	Adj. prop ${OR}^{b}$ (95% CI)	P
Hypertension
1^st year
PRYGB	157	0	0%	21	13%	136	87%	9.33	2.92 (1.09, 7.85)		(.033)
RRYGB	48	0	0%	15	32%	33	68%	8.40	2.92 (1.09, 7.85)		(.033)
5^th year
PRYGB	157	0	0%	16	10%	141	90%	9.50	2.90		(.099)
RRYGB	48	4	8%	7	14%	37	76%	8.35	(0.82, 10.26)
Dyslipidemia
1st year
PRYGB	122	0	0%	25	20%	97	80%	8.98	1.13 (0.46, 2.78)		(.795)
RRYGB	32	0	0%	7	22%	25	78%	8.96	1.13 (0.46, 2.78)		(.795)
5th year
PRYGB	122	0	0%	12	10%	110	90%	9.50	7.91 (1.83, 34.26)		(.006)
RRYGB	32	8	25%	4	13%	20	62%	6.88	7.91 (1.83, 34.26)		(.006)
DM
1st year
PRYGB	93	0	0%	32	35%	61	65%	8.27	0.64 (0.23, 1.78)		(.392)
RRYGB	21	0	0%	5	24%	16	76%	8.82	0.64 (0.23, 1.78)		(.392)
5^th year
PRYGB	93	0	0%	19	20%	74	80%	8.99	1.68 (0.41, 6.88)		(.466)
RRYGB	21	3	12%	2	11%	16	77%	8.21	1.68 (0.41, 6.88)		(.466)

$^{a}$ Score of improvement estimated by partial credit score method; Adj. prop. OR: proportional odds ratio adjusted by age and sex using multiple ordinal regression estimated using generalized estimation equation and weighted by inverse propensity score weights, where the primary RYGB is the reference category; DM, diabetes mellitus; PRYGB, primary Roux-en-Y gastric bypass; RRYGB, revisional Roux-en-Y gastric bypass